Gallala Hichem, Winter Jochen, Veit Nadine, Nowak Michael, Perner Sven, Courts Cornelius, Kraus Dominik, Janzen Viktor, Probstmeier Rainer
Department of Hematology/Oncology, University of Bonn, Bonn, Germany.
Tumour Biol. 2015 Apr;36(4):2725-35. doi: 10.1007/s13277-014-2897-6. Epub 2014 Dec 7.
We have recently shown that staurosporine mediates the conversion of small cell lung carcinoma (SCLC) cells into a neuron-like process-bearing phenotype. Here, we have extended these studies to the staurosporine analogs K252a, lestaurtinib, PKC412, stauprimide, and UCN-01 and analyzed their influence on process extension, cell cycle distribution, and induction of polyploidy in four SCLC cell lines. In GLC-2 cells, all compounds provoked extensive process formation with the exception of PKC412 that showed no response. In H1184 cells, process formation was predominantly induced by staurosporine and, to lesser extent, in lestaurtinib-, stauprimide-, and UCN-01-treated cells. In the presence of K252a or PKC412, cells became bipolar and spindle shaped or showed pronounced cell flattening. In GLC-36 and SCLC-24H cells, only cell flattening was detectable. Process formation was reversible upon drug removal as shown for GLC-2 and H1184 cells. Fluorescence-activated cell sorting (FACS) and fluorescence in situ hybridization (FISH) analysis indicated the induction of polyploidy in all staurosporine and in two out of four stauprimide-treated SCLC cell lines. For other staurosporine analogs, polyploidy was observed only in UCN-01-treated GLC-36 cells and in K252a-treated H1184 and GLC-36 cells. The presence of staurosporine or its analogs did not alter the constitutive activation pattern of the canonical Akt/PI3K or MEK/extracellular signal-regulated kinase (ERK)1/2 signaling pathways nor could we detect an influence of stauprimide application on the expression level of the c-Myc oncogene. These data demonstrate that in SCLC cells, albeit a higher substrate specificity, staurosporine analogs can induce staurosporine-comparable effects.
我们最近发现,星形孢菌素可介导小细胞肺癌(SCLC)细胞转变为具有神经元样突起的表型。在此,我们将这些研究扩展至星形孢菌素类似物K252a、来他替尼、PKC412、司他普明和UCN - 01,并分析了它们对四种SCLC细胞系中突起延伸、细胞周期分布及多倍体诱导的影响。在GLC - 2细胞中,除无反应的PKC412外,所有化合物均引发广泛的突起形成。在H1184细胞中,突起形成主要由星形孢菌素诱导,来他替尼、司他普明和UCN - 01处理的细胞中诱导程度较小。在K252a或PKC412存在的情况下,细胞变为双极和纺锤形,或表现出明显的细胞扁平。在GLC - 36和SCLC - 24H细胞中,仅可检测到细胞扁平。如GLC - 2和H1184细胞所示,药物去除后突起形成是可逆的。荧光激活细胞分选(FACS)和荧光原位杂交(FISH)分析表明,所有星形孢菌素及四种司他普明处理的SCLC细胞系中的两种可诱导多倍体。对于其他星形孢菌素类似物,仅在UCN - 01处理的GLC - 36细胞以及K252a处理的H1184和GLC - 36细胞中观察到多倍体。星形孢菌素或其类似物的存在并未改变经典Akt/PI3K或MEK/细胞外信号调节激酶(ERK)1/2信号通路的组成性激活模式,我们也未检测到司他普明应用对c - Myc癌基因表达水平的影响。这些数据表明,在SCLC细胞中,尽管底物特异性较高,但星形孢菌素类似物可诱导与星形孢菌素类似的效应。